上海莱士: 关于向银行申请并购贷款的公告

Group 1 - The core point of the announcement is that Shanghai Laishi plans to acquire 100% equity of Nanyue Biopharmaceutical Co., Ltd. for a base price of 4.2 billion RMB and a contingent payment of 50 million RMB, using self-raised funds [1][2] - The acquisition was approved during the board meeting held on March 25, 2025, and Nanyue Biopharmaceutical will become a wholly-owned subsidiary of Shanghai Laishi upon completion [1][2] - The company intends to apply for a merger loan from large listed banks and national joint-stock commercial banks to finance the acquisition and replace previously paid equity purchase prices [2] Group 2 - The application for the merger loan aligns with the company's operational needs and structured financing arrangements, supporting future funding plans and business expansion [2] - The company currently has a good operational status and debt repayment capability, indicating that the merger loan will not pose significant financial risks [2]